It is a scientifically proven fact that one's own ‘Cord Blood' cannot be used for transplant in most blood related disorders as majority of conditions are genetic or inherited. In fact, the cord blood in such a case needs to be discarded.
Leading stem cell research organization Mycord, an initiave of Cellugen Biotech, is redefining umbilical cord blood banking in India by introducing the Mycord Precious Pool Plan, a new concept that will create a large private pool of umbilical cord blood units. The pool will allow its members, access to other best matched cord blood samples, rather than just their own.
The initiative is a revolutionary break from the current practice of private cord blood banks that allow a person access to only their own cord blood, making stem cell transplants unviable in a majority of cases. However, Mycord is not just a cord blood bank; it also proposes to utilize the banked cord blood, cord tissue and amniotic membrane for potential therapeutic use.
Umbilical Cord Blood Transplant (UCBT) has gained popularity as an efficacious treatment modality for various malignant and non-malignant hematological disorders, since the first successful UCBT was done in France in 1988. More than 35,000 successful cord blood transplants have since been performed worldwide .
There are at least 142 public and 25 private UCB banks the world over with 3 public and 7 private banks located in India. In India, insufficient quantity of just about 5000 cord blood units are available in public banks.The chance of obtaining a matched donor for an Indian recipient from foreign registries is meager due to ethnicity and exorbitant cost. Till date, only 32 patients have received a transplant using related or unrelated UCB.